I got the feeling from the Cohen call that they're MNTA trials, and they're bio-equivelence trials, not efficacy/safety. Whether Mylan does some too I don't think will carry any weight, since i'm pretty sure these are MNTA's and CW reiterated emphatically they're still on the j pathway and he hasn't seen anything to make him think otherwise.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.